Shattuck Labs (STTK)

• Market cap: $46M
• 1 day: 3.51%
• 5 days: -1.61%
• 1 month: 17.43%
• 3 months: -13.59%
• 6 months: -47.97%
• Year to date: -17.88%
• 1 year: -72.47%
• 5 years: -94.86%
• 10 years: -94.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Employees: 44

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

5.63% less ownership

Funds ownership: 65.11% [Q1] → 59.48% (-5.63%) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

20% less funds holding

Funds holding: 75 [Q1] → 60 (-15) [Q2]

24% less capital invested

Capital invested by funds: $29.6M [Q1] → $22.5M (-$7.13M) [Q2]

56% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 25

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 101% upside
• Avg. target: $2 101% upside
• High target: $2 101% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Leerink Partners Faisal Khurshid

101% upside $2

Outperform Maintained

14 Aug 2025